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Abstract
Background: Statins are perceived as potential etiological factors for acute pancreatitis (AP), but recent evidence suggests
the opposite. Our aim was to evaluate the association between statin use and risk of AP in observational studies.
Methods: Medline, Scopus, and Web of Science were searched for cohort (C) and case-control (CC) studies evaluating statins
as intervention and AP as outcome. Pooled adjusted odds ratios (ORs) with corresponding 95% confidence intervals (CIs)
were calculated.
Results: Thirteen studies (seven CC, six C) with 34,899 AP patients and 5,377,894 controls were included. Prevalence of statin
use was 9.8% among AP patients and 25% among controls. Pooled adjusted OR was 1.00 (95% CI ¼ 0.63 to 1.59) with
considerable heterogeneity (I2¼ 98%). CC studies were associated with increased AP risk (OR¼ 1.33; 95% CI¼ 1.20 to 1.47),
unlike C studies (OR¼ 0.69; 95% CI¼ 0.37 to 1.31). No association with increased risk was found for studies from Western
countries (OR¼ 0.90; 95% CI¼ 0.52 to 1.56), unlike for studies conducted in Asia (OR¼ 1.39; 95% CI¼ 1.10 to 1.75).
Conclusion: Statin use is not associated with increased risk of AP. Increased risk was limited to CC studies, which are more
prone to bias, while C studies showed no global effect. Further research is needed to clarify whether statin type, dosage,
treatment duration or AP etiology might account for this difference.
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Key summary
. Statins are widely perceived as risk factors for developing acute pancreatitis (AP), but this is mainly based
on weak scientiﬁc evidence.
. Recent evidence suggests that pleiotropic eﬀects of statins, such as anti-inﬂammatory, may have a pro-
tective role against AP.
. Data from observational studies do not conﬁrm a signiﬁcant association between statins and risk of
developing AP.
. Additional research designed in a prospective fashion is needed to clarify whether the type of statins used,
dosage, duration of treatment and other characteristics have any eﬀects on this association.
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Introduction
Acute pancreatitis (AP) is a common inﬂammatory
gastrointestinal disease1 with rising incidence that is
most frequently caused by gallstone disease or alcohol
consumption. A variety of other etiological factors
have been reported, with medications being a relatively
uncommon cause accounting for approximately up to
2% of cases.2,3 A vast number of diﬀerent drugs have
been reported to be associated with AP. However, given
the rather low incidence of drug-induced pancreatitis,
as well as evidence being frequently based on single
case-reports and case-series studies with lack of ade-
quate epidemiological studies, these associations are
mostly uncertain and the extent of risk for disease
remains unknown.
Statins have historically been perceived as drugs that
increase the risk of AP.4,5 Statins are widely used in
various indications both for primary and secondary
prevention of cardiovascular diseases as lipid-lowering
agents that act by inhibiting the enzyme 3-hydroxy-3-
methyl-glutarl-coenzyme A reductase (HMG-CoA
reductase). More recent evidence from observational
studies supported by a meta-analysis of randomized
controlled trials suggests that statins may instead
reduce the risk of AP.6–8 A large prospective cohort
study published in 2013 showed that statin use may
be associated with a less severe course of disease and
may even decrease mortality.6 These ﬁndings are sup-
ported by both basic and clinical research ﬁndings
pointing to diﬀerent aspects of statin activity. Besides
lowering the concentration of low-density lipoprotein
cholesterol, statins also show important anti-
inﬂammatory, anti-thrombotic, antioxidant, and
anti-apoptotic eﬀects.9–11 These anti-inﬂammatory
properties are mainly acquired through decreased pro-
duction of proinﬂammatory cytokines, such as interleu-
kin 1, interleukin 6, and tumor necrosis factor alpha.12
Pathophysiologic processes during AP are based on the
same mechanisms with local ischemia and inﬂamma-
tion being responsible for development of pancreatic
necrosis and excessive cytokine release leading to sys-
temic inﬂammatory response syndrome and organ fail-
ure, which ultimately deﬁne disease severity and
mortality.13,14 Therefore, one might speculate that
statin users may beneﬁt from the described pleiotropic
eﬀects by reducing the risk of AP and improving clin-
ical outcomes once AP is established.15
The inconsistency of available data on the use of
statins and risk of AP, as well as the perception of sta-
tins being adversely related to AP by most clinicians,
justify our aim to perform a systematic review of the
literature and meta-analysis of observational studies to
assess the association between the use of statins and the
risk of developing AP. This project was developed as
part of the Pancreas 2000 Research Program.
Materials and methods
We included cohort (C) and case-control (CC) studies
irrespective of language and publication status with
available data for a quantitative synthesis. Identiﬁed
studies had to: (1) evaluate exposure to statins in a
cohort or population that included internal controls;
(2) evaluate the occurrence or diagnosis of AP; and
(3) report the relative risk (RR) or odds ratio (OR)
with conﬁdence interval (CI), or original raw data suf-
ﬁcient to evaluate the hypothesized eﬀect. The outcome
measured was the diagnosis of AP. The exposure
assessed included the use of statins regardless of the
type, dosage and length of exposure.
We conducted electronic searches of Medline, Web
of Science and Scopus from inception to April
2017. The speciﬁc search strategies are detailed in
Appendix 1. Two authors independently screened
titles of identiﬁed studies to ascertain their relevance.
Abstracts and/or full texts of selected potentially rele-
vant articles were further assessed for inclusion and
exclusion criteria. Reference lists of the identiﬁed rele-
vant articles were hand-searched to look for additional
studies. Disagreements regarding study inclusion were
solved by consulting a third review author.
Two review authors extracted and validated data
independently using extraction sheet forms designed
speciﬁcally for this purpose. For studies reported in
more than one publication, the one with the most com-
plete data was used. Potential disparities within the
extracted data were resolved by discussion and consult-
ation with a third author. The following data from
included studies were extracted: (1) study: year of pub-
lication, language, study accrual period, and study
design; (2) cases: number, gender, age, deﬁnition
(i.e. patient records, clinical charts, or other means),
and severity of acute pancreatitis; (3) controls:
number, source, and matching design; (4) exposure:
deﬁnition, type, dosage, and length; and (5) type of
outcome measure. Quality assessment was performed
using the Newcastle-Ottawa scale for CC and C studies.
Studies achieving a score> 6 were deﬁned as studies of
high methodological quality and low risk of bias, while
studies with a lesser score were categorized as low qual-
ity and high risk of bias studies.
A meta-analysis of included studies was performed
using the software package Comprehensive
Meta-Analysis (Biostat, Englewood, NJ, USA).
Calculations of the pooled estimates (OR with 95%
CI) were performed using the DerSimonian-Liard
method and a random-eﬀects model. In addition to
within-study variance, the random-eﬀects model con-
siders heterogeneity among studies and gives more con-
servative estimates. The quantity of heterogeneity was
assessed by means of the I2 value. The I2 describes the
percentage of total variation across studies that is
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caused by heterogeneity and not by chance. An I2 value
of 25% or lower was considered as trivial heterogen-
eity, and an I2 value of 75% or higher as important
heterogeneity. A p value< 0.05 was accepted as statis-
tically signiﬁcant. Planned sensitivity analyses were per-
formed regarding type of study (CC vs C), country of
origin (Western countries vs Asian countries), and
quality assessment (high vs low quality). We assessed
reporting bias by using the Begg and Mazumdar test.
On a post-hoc basis a sensitivity analysis among C stu-
dies was performed by exclusion of the Wu et al.16
study based on a largely diﬀerent eﬀect estimate and
high heterogeneity among included studies.
Results
A total of 1796 records were identiﬁed through elec-
tronic database search. We excluded 1716 duplicates
or clearly irrelevant studies by reading titles and
abstracts. The remaining 80 records were assessed for
eligibility and an additional 67 studies were excluded
because they did not meet inclusion criteria. Of the
remaining 13 studies that contributed to the ﬁnal
meta-analysis, seven were CC studies and six were C
studies (Figure 1). A total of 34,899 patients with AP
and 5,377,894 controls were included. A summary of
included studies with study information, baseline popu-
lation characteristics, type of exposure, data synthesis
and quality assessment scores are provided in Table 1.
The pooled prevalence of statin use was 9.8% (3411/
34,899) among AP patients and 25% (1,357,175/
5,377,894) among controls. The overall analysis
showed no signiﬁcant eﬀect of statins on the occurrence
of AP with a pooled OR 1.00 (95% CI 0.63 to 1.59)
and extremely high heterogeneity across studies
(I 2¼ 98.6%) (Figure 2). However, when separating
the analysis according to study design, CC studies con-
ﬁrmed a signiﬁcant diﬀerence, with a 32.6% increased
Records identified
through database
search
n = 1796
Records screened
n = 1796
Records assessed for eligibility
n = 80
Studies considered for qualitative
synthesis
n = 13
Studies included in qualitative
synthesis
n = 13
Excluded (cohort overlap)
n = 0
Studies included in quantitative
synthesis (meta-analysis)
n = 13
Excluded (did not fulfill
inclusion criteria)
n = 67
Records excluded (not
related to study topic)
n = 1716
Additional records identified
from conference abstracts
n = 0
Figure 1. Database search and selection of studies.
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risk of AP among statin users. Out of 26,147 cases of
AP, statins were used by 1666 patients compared to
4228 statin users among 89,871 controls (OR 1.33;
95% CI 1.99 to 1.47; p< 0.0001; I 2¼ 34.5%). C studies,
on the other hand, showed a nonsigniﬁcant 31% risk
reduction for AP among patients taking statins with
1745 out of 8752 cases of AP taking statins compared
to 1,352,947 out of 5,288,023 controls (OR 0.69; 95%
CI 0.37 to 1.31; p¼ 0.26; I 2¼ 97.3%). A post-hoc ana-
lysis of cohort studies with exclusion of the Wu et al.16
study showed a signiﬁcant reduction in the incidence of
AP with OR 0.86 (95% CI 0.75 to 0.99; p¼ 0.03) and
no heterogeneity (I 2¼ 0%).
Subgroup analysis based on country of origin
showed an increased risk of AP associated with the
use of statins within studies performed in Asian coun-
tries with an OR 1.39 (95% CI 1.10 to 1.75; p¼ 0.006)
(Figure 3). This analysis is based on three studies with
rather high heterogeneity (I 2¼ 76.3%). Ten studies ori-
ginating from Western European and North American
countries proved no signiﬁcant diﬀerence of occurrence
of AP between statin users and non-users OR 0.90
(95% CI 0.52 to 1.56; p¼ 0.71), again showing high het-
erogeneity between the included studies (I 2¼ 98.5%)
(Figure 4).
Four studies16,19,29,30 were assessed as high quality,
and meta-analysis of this subgroup showed no signiﬁ-
cant eﬀect of statins on risk of AP (OR 0.71; 95% CI
0.24 to 2.05; p¼ 0.52) and extreme heterogeneity
(I2¼ 99%). The rest of the included studies were
judged as of lower quality and with higher risk of
bias. No signiﬁcant diﬀerence in occurrence of AP
between statin users and non-users was noted either
(OR 1.14; 95% CI 0.95 to 1.38; p¼ 0.16), with hetero-
geneity being high (I2¼ 75%).
There was evidence of a publication bias, with stu-
dies reporting an increased risk of AP associated with
the use of statins more likely to be published than stu-
dies with negative results (Kendall’s tau¼ –0.55:
p¼ 0.006) (see funnel plot in Figure 5).
Discussion
This is the ﬁrst meta-analysis of observational studies
analyzing the association between the use of statins and
the risk of developing AP. The present results do not
suggest a signiﬁcant association between statin use and
the risk of AP. Our results of an apparent risk limited
to CC studies, with a trend toward a possible protective
eﬀect in C studies, might be related to the fact that CC
studies are more prone to bias. Based on the present
ﬁndings, and on available conﬂicting results of previ-
ously published research, it is not possible to determine
whether statins act as risk factors for AP or have a
protective role.Ta
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As anticipated, tests for heterogeneity showed an
extremely high percentage of total variation across stu-
dies, despite using a random-eﬀects model. We tried to
investigate this heterogeneity by performing diﬀerent
pre-planned sensitivity analyses. When dividing the stu-
dies based on design, a high heterogeneity persisted
among C studies. Most C studies reported no signiﬁ-
cant diﬀerence between the compared groups, except
for the Wu et al.16 study, which demonstrated a signiﬁ-
cant risk reduction of AP among statin users.
Therefore, we made a post-hoc sensitivity analysis by
excluding the Wu et al.16 study. Such meta-analysis
showed a signiﬁcant reduction of the incidence of AP
among statin users. This can be explained by null
heterogeneity among studies and consequent use of
the ﬁxed-eﬀect model of meta-analysis in contrast to
the original meta-analysis of C studies that was aﬀected
by high heterogeneity and a random-eﬀects model had
to be used. Besides the clear diﬀerences in methodo-
logical quality, there are substantial diﬀerences in
study populations as well. In the Smeeth et al.30
study, a population-based cohort is compared to con-
trols from large randomized trials, while the Pulkkinen
et al.28 study used only symptomatic gallstone patients
as controls. Other studies based their analysis on data
obtained from various health care system registries.
Sensitivity analysis according to country of origin
showed that in studies performed in Asian countries
Study name Statistics for each study
Odds
ratio
Douros simvastatin 1,300
1,000
0,670
1,250
1,760
1,330
1,100
1,180
0,950
0,910
0,911
0,910
1,440
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Figure 2. Overall analysis with pooled odds ratio (OR) showing no significant influence of statins on occurrence of acute pancreatitis (AP),
with 3411 of statin users among 34,899 cases of AP compared to 1,357,175 out of 5,377,894 controls (OR 1.00; 95% confidence interval (CI)
0.63 to 1.59; p¼ 0.99; I 2¼ 98.6%).
Study name
Odds
ratio
Lai 2015 1,760
1,330
1,180
1,389
1,409
1,071
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2,581
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Statistics for each study Odds ratio and 95% CI
Figure 3. Subgroup analysis of studies from Asian countries indicating that use of statins significantly increases the risk of acute
pancreatitis (693/15,420 cases vs 726/32,435 controls).
CI: confidence interval; OR: odds ratio.
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the use of statins is associated with an increased risk of
AP. However, this result is based on only three CC
studies with potential high risk of bias. All other
included studies originating from Western
European and North American countries conﬁrmed
no speciﬁc association between the use of statins
and risk of AP. However, this sensitivity analysis does
not contribute to the explanation of the observed het-
erogeneity, which was still important in these
subgroups.
Indeed, as the performed sensitivity analyses only
partly explain the high heterogeneity between studies,
other potential confounding factors could have aﬀected
the results including type and dosage of statin used,
duration and compliance with treatment, deﬁnition
and etiology of AP, missing data, comorbidities and
other risk factors aﬀecting clinical outcomes of
included participants.
Among these factors, the deﬁnition of AP might rep-
resent a critical limitation of some studies, as an
increase of circulating levels of pancreatic enzymes
might have been erroneously associated with the diag-
nosis of AP in some instances, especially in retrospect-
ive studies based in registries.
Notably, most of the included studies have been
assessed as being of low methodological quality. In
most instances, the studies failed to report an adequate
deﬁnition of cases and to clarify the representativeness
of the exposed cohort. Furthermore, lack of adequate
outcome assessment and ascertainment of exposure was
present in most of the included studies.
Our results do not support the ﬁndings from two
previous systematic reviews and meta-analyses. Singh
and Loke5 showed an association between statin use
and an increased risk of AP, but their results were
based mainly on individual case reports and only two
observational studies. On the contrary, a more recent
meta-analysis of randomized controlled trials showed a
protective role of statins regarding the risk of AP.7
Whether randomized trials are the best option and
source of data to assess this association is debatable,
since patients are carefully selected and often do not
reﬂect actual real-life circumstances. Furthermore, ran-
domized trials are usually not designed to assess
adverse events, especially not rare ones and these are
often not adequately reported, which may lead to
potentially biased results.
Study name Statistics for each study Odds ratio and 95% CI
Odds
ratio
Lower
limit
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limit Z -Value p -Value
Douros simvastatin 1,300 0,602
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0,499
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Figure 4. Forest plot showing results of subgroup analysis performed on studies originating from Western European and North American
countries. Meta-analysis showed no significant influence of statins on occurrence of acute pancreatitis. We compared 2718/19,479 cases vs
1,356,449/5,345,459 controls receiving statin treatment.
CI: confidence interval; OR: odds ratio.
Funnel plot of standard error by log odds ratio
0.0
0.5
St
an
da
rd
 e
rro
r
1.0
1.5
2.0
–3 –2 –1 0 1
Log odds ratio
2 3
Figure 5. Funnel plot for sensitivity analysis assessing publication
bias indicating that studies showing an increased risk of acute
pancreatitis among statin users were more likely to be published
than studies showing no association (Kendall’s tau¼ –0.55:
p¼ 0.006).
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In conclusion, this meta-analysis of observational
studies is the largest performed to date showing that
available data do not conﬁrm a signiﬁcant association
between the use of statins and the risk of AP. Statins
are probably less hazardous than thought in the past,
especially because evidence on which such perceptions
were based was of very low quality. Further research
designed to prospectively evaluate the occurrence of AP
among statins users is needed to clarify potential bene-
ﬁcial or harmful eﬀects of statins and to adequately
assess whether the type of statins used, dosage, dur-
ation of treatment and other characteristics have any
eﬀects on this association. In this regard, the ongoing
Simvastin in the Prevention of Recurrent Acute
Pancreatitis, a Triple-Blind Randomized Controlled
Trial (SIMBA) will help to ascertain the role of statins
in inﬂammatory pancreatic disease; SIMBA is a multi-
center, randomized, triple-blind trial aiming to com-
pare the incidence of new episodes of AP among
patients consuming simvastatin vs placebo.15
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Appendix 1. Search strategies
Medline
1. pancreatitis.mp.
2. exp Pancreatitis/
3. or/1-2
4. exp Hydroxymethyglutaryl-CoA Reductase
Inhibitors/
5. Hydroxymethyglutaryl-CoA Reductase
Inhibitors.mp.
6. Hydroxymethyglutaryl-CoA Reductase*.mp.
7. HMG-CoA Reductase Inhibitor*.mp.
8. atorvastatin.mp.
9. exp Atorvastatin/
10. ﬂuvastatin.mp.
11. lovastatin.mp.
12. exp Lovastatin/
13. pitavastatin.mp.
14. pravastatin.mp.
15. exp Pravastatin/
16. rosuvastatin.mp.
17. exp Rosuvastatin/
18. simvastatin.mp.
19. exp Simvastatin/
20. statin*.mp.
21. exp Statins/
22. or/4-21
23. 3 and 22
Scopus
ALL (‘‘acute pancreatitis’’) OR ALL (‘‘pancreatitis’’)
AND ALL (‘‘hydroxymethylglutaryl-CoA reduc-
tase*’’) OR ALL (‘‘HMG-CoA reductase*’’) OR ALL
(‘‘atorvastatin’’) OR ALL (‘‘ﬂuvastatin’’) OR ALL
(‘‘lovastatin’’) OR ALL (‘‘pitavastatin’’) OR
ALL (‘‘pravastatin’’) OR ALL (‘‘rosuvastatin’’) OR
ALL (‘‘simvastatin’’) OR ALL (‘‘statin*’’)
Web of Science
1. TS¼pancreatitis
2. TS¼(HMG CoA reductase inhibitor*)
3. TS¼(hydroxy* CoA reductase inhibitor*)
4. TS¼(hydroxy* CoA reductase*)
5. TS¼atorvastatin
6. TS¼ﬂuvastatin
7. TS¼lovastatin
8. TS¼pitavastatin
9. TS¼pravastatin
10. TS¼rosuvastatin
11. TS¼simvastatin
12. TS¼statin*
13. 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. 1 and 13
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